Purpose: Resveratrol (Calbiochem, La Jolla, California) is a naturally occurring stilbene reported to cause apoptosis in various cultured cancer cells. In the current study the effect of resveratrol was determined in the androgen insensitive DU 145 prostate cancer cell line. Induction of apoptosis and activation of apoptosis related signal transduction pathways were measured. Materials and Methods: DU 145 cells were treated with resveratrol and apoptosis was measured by determining nucleosome content. Activation of mitogen activated protein kinase (MAPK) (extracellular signal-regulated kinase 1/2), p53 content and serine-15 phosphorylation of p53 were measured by immunoblot. Electrophoretic mobility shift assay of p53 binding to DNA, and measurement of p21 and glyceraldehyde-3-phosphate dehydrogenase messenger RNA were also done. Results: Resveratrol induced apoptosis in DU 145 cells. The stilbene activated MAPK and caused increased abundance of p53 and serine-15 phosphorylated p53. Resveratrol induced serine-15 phosphorylation of p53 was blocked by PD 98059 (Calblochem), a MAPK kinase inhibitor, implicating MAPK activation in the phosphorylation of p53. PD 98059 also inhibited resveratrol induced apoptosis. These results suggest that apoptosis induction by resveratrol in DU 145 cells requires serine-15 phosphorylation of p53 by MAPK. Inhibition of MAPK dependent serine-15 phosphorylation resulted in reduced p53 binding to a p53 specific oligonucleotide on electrophoretic mobility shift assay. Pifithrin-alpha (Calbiochem), a p53 inhibitor, blocked resveratrol induced serine-15 phosphorylation of p53 and p53 binding to DNA. Resveratrol caused a p53 stimulated increase in p21 messenger RNA. Transfection of additional wild-type p53 into DU 145 cells induced apoptosis, which was further enhanced by resveratrol treatment. Conclusions: Resveratrol causes apoptosis in DU 145 prostate cancer cells. This action depends on the activation of MAPK, increase p53 binding to DNA.
机构:
Tanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, JapanTanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, Japan
Sugikawa, E
Yazaki, N
论文数: 0引用数: 0
h-index: 0
机构:
Tanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, JapanTanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, Japan
Yazaki, N
Tsunoda, S
论文数: 0引用数: 0
h-index: 0
机构:
Tanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, JapanTanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, Japan
Tsunoda, S
Nakanishi, N
论文数: 0引用数: 0
h-index: 0
机构:
Tanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, JapanTanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, Japan
Nakanishi, N
Ohashi, M
论文数: 0引用数: 0
h-index: 0
机构:
Tanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, JapanTanabe Seiyaku Co Ltd, Drug Discovery Res Lab, Toda, Saitama 3358505, Japan
机构:
Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan
Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, JapanKanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan
Nakayama, Mizuho
Oshima, Masanobu
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan
Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, JapanKanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan